

Appln. No. 09/537,858
Supplemental Amdt. dated December 21, 2004
Reply to Office action of April 15, 2004

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Pending Claims Appln. 09/537,858 (PROOST1)

1-24 (Canceled)

25 (Currently Amended). An isolated amino-terminally truncated RANTES polypeptide consisting of residues 3-68 of a RANTES polypeptide according to SEQ ID NO:1, wherein the truncated RANTES polypeptide lacks NH₂-terminal amino acid residues 1-2 and has ~~RANTES antagonistic activity~~ the ability to inhibit monocyte cell chemotaxis towards CC chemokines, and the ability to retain the capacity of intact RANTES to bind CCR5.

26-27 (Canceled)

28 (Previously Presented). The isolated amino-terminally truncated RANTES of claim 25, wherein the truncated RANTES polypeptide is in glycosylated form.

29 (Previously Presented). A pharmaceutical composition comprising an isolated truncated RANTES polypeptide according to claim 25, wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.

Appln. No. 09/537,858
Supplemental Amdt. dated December 21, 2004
Reply to Office action of April 15, 2004

30 (Previously Presented). The pharmaceutical composition according to claim 29, wherein the isolated truncated RANTES polypeptide is in glycosylated form.

31 (New). A method for the treatment of an inflammatory disease, HIV-infection, an angiogenic- or hematopoiesis-related disease, or a tumor, in a patient in need, comprising administering to the patient an effective amount of an amino-terminally truncated RANTES polypeptide in accordance with claim 25.

32 (New). A method in accordance with claim 31 for the treatment of an inflammatory disease, wherein the patient in need is one suffering from an inflammatory disease.

33 (New). A method in accordance with claim 31 for the treatment of an HIV infection, wherein the patient in need is one suffering from an HIV infection.

34 (New). A method in accordance with claim 31 for the treatment of an angiogenesis- or hemotopoiesis-related disease, wherein the patient in need is one suffering from an angiogenesis- or hemotopoiesis-related disease.

35 (New). A method in accordance with claim 31 for the treatment of a tumor, wherein the patient in need is one suffering from a tumor.